Dhanuka Agritech Ltd

- No explicit mention of current or future fundraising through debt or equity was made in the transcript. - A INR 50 crore loan facility was approved for Dhanuka Laboratories, but it is indicated as an approval for occasional use rather than a new fundraising. - Discussions around capex for the Dahej plant indicate plans for fresh capital expenditure based on R&D product development but no mention of specific fundraising methods. - The company is focusing on internal cash deployment for investments, buybacks, and dividends, maintaining cash at a similar level in recent years. - No announcements or indications were provided regarding raising equity or additional debt fundraising in the near term.

- The Dahej plant has 2 phases of capex planned; the second phase may start next year or in 2026. - The company will not wait for international CDMO collaboration projects to begin fresh capex; instead, new products from R&D reaching maturity will trigger fresh investments, possibly starting next FY. - The current Dahej plant can add 2-3 more products and is multipurpose with capacity to manufacture 4-5 products simultaneously. - Fresh capex depends on the pace of product development in R&D. - The company is actively working on new technical products including bifenthrin and expects to increase revenue from these products. - There is an ongoing loan facility of around INR 50 crores for Dhanuka Laboratories, already approved for operational needs. - No current product revenue from Dahej plant as of Q2, but cost impact was around INR 5-6 crores.

- New product introductions are expected to drive future growth, with revenue from new products forecasted to exceed 20-25% by FY '25-'26. - Volume growth in Q2 was strong at 20%, with H1 volume growth around 10%; momentum is expected to continue into H2. - There is confidence in sustaining top-line growth and improving EBITDA margins by approximately 200 basis points by year-end due to product mix and margin improvements. - The Rabi season, especially in South and East India, offers strong opportunities for key products like Defend, Decide, Mesotrax, and Implode. - Maize and chilli markets are growing, with maize herbicides and insecticides targeting high-value crops offering large upside. - Capacity is sufficient to almost double revenue with current formulation capacity without immediate capex. - Fresh capex for additional products will depend on R&D product pipeline maturity, expected possibly from next financial year.

- The company expects new product revenues to increase substantially, potentially crossing 25% of total revenue by FY '25/'26, contingent on decent rainfall. - Volume growth was strong at 20% in Q2, with consistent focus on innovative products contributing to margin improvement. - Gross margin expansion is projected, driven by product mix and inventory normalization, with an anticipated 200 basis points margin improvement by year-end. - Fresh capital expenditure is planned in the next financial year, aligned with new product development and R&D progress. - Confident outlook for strong performance in H2 FY '24 due to key products like Decide, Defend, Implode, and Mesotrax gaining traction, especially in crops like maize, chilli, and paddy. - EBITDA margin guidance remains positive with expected incremental margin improvement of around 150-200 basis points. - The company aims to deliver around INR 100 crore revenue from bifenthrin in FY '25.

- The transcript does not explicitly mention the current or expected order book or pending orders for Dhanuka Agritech Limited. - However, it highlights that the company has several products in its development pipeline and plans for fresh capex depending on R&D progress (Page 17). - The company is working closely on drone technology with a partner company, indicating potential future collaboration but no specific orderbook info (Page 17). - Discussions around sales show good volume growth (20% in Q2) and clean channel inventory with stocks aligned to consumption, implying a stable order flow but no detailed pending order data (Pages 12,13). - Overall, no direct quantitative details on order book or pending orders were disclosed in the call transcript provided.